Biovica: Commercial progress and secured growth capital - Redeye

Biovca has secured the rights and direct share issues, and the company raises SEK 122m before the cost to support the US clinical sales progress for DiviTum. Our reduced Base Case at SEK 2.3 (2.6) with a Bull Case of SEK 11 and a Bear Case of SEK 0.30 ( Bull SEK 18, Bear SEK 0.50) reflects the increased number of shares.

Länk till analysen i sin helhet: https://www.redeye.se/research/1122656/biovica-commercial-progress-and-secured-growth-capital?utm_source=finwire&utm_medium=RSS